Bisphosphonates (BPs) are well established as the leading drugs for the treatment of
osteoporosis. There is new knowledge about how they work. The differences that exist among …

The bisphosphonates (BPs) are well established as the treatments of choice for disorders of
excessive bone resorption, including Paget's disease of bone, myeloma and bone …

The ability of bisphosphonates ((HO) 2 P(O)CR 1 R 2 P(O)(OH) 2 ) to inhibit bone resorption
has been known since the 1960s, but it is only recently that a detailed molecular …

Bisphosphonates are now the most widely used drugs for diseases associated with
increased bone resorption, such as osteoporosis. Although bisphosphonates act directly on …

… The potent antiresorptive N-BP NE58025 adopts a rigid three-dimensional conformation
with the nitrogen atom located at a fixed position (Ebetino et al., 1993). A … Ebetino FH and …

The molecular mechanisms by which tumor cells metastasize to bone are likely to involve
invasion, cell adhesion to bone, and the release of soluble mediators from tumor cells that …

Osteoporosis and low bone mass are currently estimated to be a major public health risk
affecting >50% of the female population over the age of 50. Because of their bone-selective …

Osteoclasts are large multinucleated bone-resorbing cells formed by the fusion of monocyte/macrophage-derived
precursors that are thought to undergo apoptosis once resorption is …

Recent evidence suggests that bisphosphonates (BPs) may inhibit bone resorption by
mechanisms that lead to osteoclast apoptosis. We have previously shown that BPs also reduce …

Bisphosphonates (BPs) target bone due to their high affinity for calcium ions. During osteoclastic
resorption, these drugs are released from the acidified bone surface and internalised by …